WO1999045923A1 - Methods of inhibiting bone resorption - Google Patents
Methods of inhibiting bone resorption Download PDFInfo
- Publication number
- WO1999045923A1 WO1999045923A1 PCT/US1999/005061 US9905061W WO9945923A1 WO 1999045923 A1 WO1999045923 A1 WO 1999045923A1 US 9905061 W US9905061 W US 9905061W WO 9945923 A1 WO9945923 A1 WO 9945923A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hmg
- coa reductase
- group
- reductase inhibitor
- pharmaceutically acceptable
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to methods of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (hereafter ⁇ MG-CoA reductase inhibitor”) to a mammal in need thereof. More particularly, the present invention relates to methods of treating or preventing conditions or disease states involving abnormal bone resorption by administering a therapeutically effective amount of a HMG-CoA reductase inhibitor.
- ⁇ MG-CoA reductase inhibitor 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor
- a variety of conditions or disease states in humans and other mammals involve or are associated with abnormal bone resorption.
- Such disorders include, but are not limited to, osteoporosis, Paget's disease, periprosthetic bone loss or osteolysis, hypercalcemia of malignancy, osteogenesis imperfecta, osteoarthritis, and aveolar bone loss associated with periodontal disease.
- abnormal bone resorption is often an undesired side effect associated with immunosuppresive therapy and chronic glucocorticoid use.
- the most widespread of the bone resorption disorders is osteoporosis, which in its most frequent manifestation occurs in postmenopausal women.
- Osteoporosis is a systemic skeletal disease characterized by a low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility and susceptibility to fracture. Because osteoporosis, as well as other disorders associated with abnormal bone resorption, are generally chronic conditions, it is believed that appropriate therapy will generally require chronic treatment.
- Osteoclasts are responsible for causing bone loss through a process known as bone resorption. Osteoclasts are actively motile cells that migrate along the surface of bone, and that can bind to bone and secrete acids and proteases causing a resorption of mineralized bone tissue.
- Therapeutic agents that have been used to treat abnormal bone resorption, and osteoporosis in particular, include organic bisphosphonates, estrogens, calcium supplements, the peptide hormone calcitonin, and sodium fluoride. See Riggs et al., The New England J. ofMed., Vol. 327, No. 9, pp. 620-627, 1992, which is incorporated by reference herein in its entirety.
- bisphosphonates are selective inhibitors of osteoclastic bone resorption.
- the bisphosphonates are important therapeutic agents in the treatment or prevention of a variety of generalized or localized bone disorders caused by or associated with abnormal bone resorption. See H. Fleisch, Bisphosphonates In Bone Disease, From The Laboratory To The Patient, 3rd Edition, Parthenon Publishing (1997); U.S. Patent No. 4,621,077, to Rosini et al., issued November 4, 1986; U.S. Patent No. 4,922,007, to Kieczykowski et al., issued May 1, 1990; U.S. Patent No. 5,019, 651, to Kieczykowski et al, issued May 28, 1991; U.S. Patent No.
- anti-bone resorptive therapies also have disadvantages associated with them.
- Hormone replacement therapy which involves the administration of estrogen and other compounds having estrogenic activity, is often prescribed for the treatment of osteoporosis in postmenopausal women.
- hormone replacement therapy has disadvantages including an increased risk of certain cancers, such as breast cancer, and the development of deep vein thromboses.
- hormone replacement therapy is contraindicated in premonopausal women and male patients. It has been a long-held belief that the administration of calcium supplements can retard the effects of accelerated bone resorption associated with osteoporosis. However, the benefits, if any, of calcium supplementation alone are relatively small and have yet to be fully demonstrated.
- the peptide hormone calcitonin is also currently used in the treatment of postmenopausal osteoporosis.
- this hormone has a relatively high molecular weight and has the disadvantage of requiring parenteral or intranasal administration.
- many patients on calcitonin therapy develop resistance to the material associated with increased titers of antibodies that neutralize the effectiveness of the therapy.
- HMG-CoA reductase inhibitors belong to a class of cardiovascular drugs known as anticholesterolemics. Recent studies have unequivocally demonstrated that lovastatin, simvastatin, and pravastatin, which are all members of the HMG-CoA reductase inhibitor class, slow the progression of atherosclerotic lesions in the coronary and carotid arteries.
- Simvastatin and pravastatin have also been shown to reduce the risk of coronary heart disease events, and in the case of simvastatin, a highly significant reduction in the risk of coronary death and total mortality has been shown by the Scandinavian Simvastatin Survival Study.
- HMG-CoA reductase inhibitors for treating abnormal bone resorption in humans and other mammals is unknown.
- the present invention provides novel methods of treatment of abnormal bone resorption comprising administering a therapeutically effective amount of an HMG-CoA reductase inhibitor to a mammal in need thereof.
- the HMG-CoA reductase inhibitors represent a new class of drugs for treating disorders associated with abnormal bone resorption.
- -5- immunosuppresive therapy or chronic glucocorticoid use comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones, to a mammal in need thereof.
- It is another object of the present invention to provide pharmaceutical compositions useful for treating abnormal bone resorption comprising a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones, to a mammal in need thereof.
- the present invention relates to a method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.
- the present invention relates to a method of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of the combination of a HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones, to a mammal in need thereof.
- the present invention relates to a method of treating or preventing a disease state involving abnormal bone resorption.
- the present invention relates to a pharmaceutical composition comprising a therapeutically effective amount of the combination of an HMG-CoA reductase inhibitor and one or more active agents selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones.
- the invention hereof can comprise, consist of, or consist essentially of the essential as well as optional ingredients, components, and methods described herein
- Figure 1 shows the inhibition of osteoclastogenesis by lovastatin ("lova”, 1 and 10 ⁇ M) and its reversal by D,L-mevalonic acid lactone ("MVA", 1 mM) as determined using a tartrate resistant acid phosphatase fluorescence assay.
- Osteoclastogenesis is assessed using a co-culture of mouse bone marrow cells and MB 1.8 mouse osteoblasts.
- the lovastatin and D,L-mevalonic acid lactone are added to the co- cultures at days 5 and 6. Tartrate resistant acid phosphatase activity is measured on day 7.
- Treatments indicated below each bar graph are as follows: A. no treatment, B. 1 ⁇ M lovastatin, C.
- the present invention relates to methods of inhibiting abnormal bone resorption comprising administering a therapeutically effective amount of a HMG-CoA reductase inhibitor to a mammal in need thereof.
- the methods of the present invention are useful for treating or preventing disease states involving abnormal bone resorption.
- the therapeutic regimen of the present invention is administered until the desired therapeutic effect is achieved.
- the therapeutic agent useful in the present invention is a compound which inhibits HMG-CoA reductase.
- Compounds which have inhibitory activity for HMG-CoA reductase can be readily identified by using assays well-known in the art. See U.S. Patent No. 4,231,938, to Monoghan et al., issued November 4, 1980 and U.S. Patent No. 5,354,772, to Kathawal, issued October 11, 1994, both of which are incorporated by reference herein in their entirety.
- HMG-CoA reductase inhibitors that are useful herein include but are not limited to lovastatin (MEVACOR®; see U.S. Patent No. 4,231,938, already cited above and incorporated by reference herein), simvastatin (ZOCOR®; see U.S. Patent No. 4,444,784, to Hoffman et al., issued April 24, 1984), pravastatin (PRAVACHOL®; see U.S. Patent No. 4,346,227, to Terahara et al., issued August 24, 1982), fluvastatin (LESCOL®; see U.S. Patent No.
- HMG-CoA reductase inhibitor is intended to include all pharmaceutically acceptable salts, esters and lactone forms of compounds which have HMG-CoA reductase inhibitory activity, and therefor the use of such salts, esters and lactone forms is included within the scope of this invention.
- the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, mevastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof. More preferably, the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof. More preferably, the HMG-CoA reductase inhibitor is selected from the group consisting of lovastatin, simvastatin, and the pharmaceutically acceptable salts, esters, and lactones thereof, and mixtures thereof.
- HMG-CoA reductase inhibitors can be represented by the chemical formula
- Z is selected from the group consisting of:
- Rl is Ci-Cio alkyl
- R2 is selected from the group consisting of C1-C3 alkyl, hydroxy, oxo, and C1-C3 hydroxy substituted alkyl,
- R3 is selected from the group consisting of hydrogen, hydroxy, C1-C3 alkyl, and C1-C3 hydroxy substituted alkyl, a, b, c, and d are all single bonds, or a and c are double bonds, or b and d are double bonds, or one of a, b, c, and d is a double bond, and n is 0, 1, or 2; b)
- R4 and R5 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, C1-C4 alkyl, C1-C4 alkoxy, and trifluoromethyl
- R ⁇ . an R9 are each independently selected from the group consisting of hydrogen, fluorine, chlorine, bromine, iodine, C1-C4 alkyl, and C1-C4 alkoxy. See U.S.
- the pharmaceutically acceptable salts, esters, and lactone forms of the compounds depicted by the preceding chemical formulas are intended to be within the scope of the present invention.
- pharmaceutically acceptable salts as used herein in referring to the HMG-CoA reductase inhibitors shall mean non-toxic salts of the compounds employed in this invention which are generally prepared by reacting the free acid with a suitable organic or inorganic base.
- salt forms of HMG-CoA reductase inhibitors include, but are not limited to, acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycollylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynapthoate, iodide, isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, mucate, napsylate, nitrate, ole
- esters as used herein in referring to the HMG- CoA reductase inhibitors is used in its standard meaning to denote the condensation product of a carboxylic acid and an alcohol. Ester derivatives of the described compounds can function as prodrugs which, when absorbed into the bloodstream of a warm-blooded animal, can cleave in such a manner as to release the drug form and permit the drug to afford improved therapeutic efficacy.
- lactones is used herein in referring to the HMG-
- CoA reductase inhibitors is used in its standard meaning to denote a cyclic condensation product of a carboxylic acid and an alcohol, i.e. a cyclic ester.
- therapeutically effective amount means that amount of the HMG-CoA reductase inhibitor or that amount of the combination of an HMG-CoA reductase inhibitor and one or more active agents that will elicit the desired biological or medical effect or response sought by a medical doctor, clinician, veterinarian, researcher, or other appropriate professional, when administered in accordance with the desired treatment regimen.
- a preferred therapeutically effective amount is a bone resorption inhibiting amount.
- therapeutically effective amount is also intended to encompass prophylactically effective amounts, i.e. amounts that are suitable for preventing a disease state or condition, if a prophylactic or prevention benefit is desired.
- abnormal bone resorption means a degree of bone resorption that exceeds the degree of bone formation, either locally, or in the skeleton as a whole.
- abnormal bone resorption can be associated with the formation of bone having an abnormal structure.
- bone resorption inhibiting means preventing bone resorption by the direct or indirect alteration of osteoclast formation or activity. Inhibition of bone resorption refers to prevention of bone loss, especially the inhibition of removal of existing
- -12- bone either from the mineral phase and/or the organic matrix phase, through direct or indirect alteration of osteoclast formation or activity.
- bone resorption inhibiting amount means that amount of the HMG-CoA reductase inhibitor that will elicit a bone resorption inhibiting effect.
- the term "until the desired therapeutic effect is achieved”, as used herein, means that the HMG-CoA reductase inhibitor or the combination with another active agent is administered, according to the dosing schedule chosen, up to the time that the clinical or medical effect sought for the disease or condition being treated or prevented is observed by the clinician or researcher.
- the HMG-CoA reductase inhibitor compound or combination is continuously administered until the desired change in bone mass or structure is observed. In such instances, achieving an increase in bone mass or a replacement of abnormal bone structure with normal bone structure are the desired objectives.
- the HMG-CoA reductase inhibitor compound or combination is continuously administered for as long as necessary to prevent the undesired condition or disease state.
- Nonlimiting examples of treatment and prevention administration periods can range from about 2 weeks to the remaining lifespan of the mammal.
- administration periods can range from about 2 weeks to the remaining lifespan of the human, preferably from about 2 weeks to about 20 years, more preferably from about 1 month to about 20 years, more preferably from about 6 months to about 10 years, and most preferably from about 1 year to about 10 years.
- the dosage regimen utilizing a HMG-CoA reductase inhibitor or the combination with another active agent is selected in accordance with a variety of factors including type, species, age, weight, sex and medical condition of the patient; the severity of the condition to be treated; the route of administration; the renal and hepatic function of the patient; and the particular compound or salt or ester thereof employed. A consideration of these factors is well within the purview of the ordinarily skilled clinician for the purpose of determining the
- patient includes mammals, especially humans, who take an HMG-CoA reductase inhibitor or combination for any of the uses described herein.
- Administering of the drug or drugs to the patient includes both self- administration and administration to the patient by another person.
- the precise dosage of the HMG-CoA reductase inhibitor or the combination with another active agent will vary with the dosing schedule, the particular compound chosen, the age, size, sex and condition of the mammal or human, the nature and severity of the disorder to be treated, and other relevant medical and physical factors.
- a precise pharmaceutically effective amount cannot be specified in advance and can be readily determined by the caregiver or clinician. Appropriate amounts can be determined by routine experimentation from animal models and human clinical studies.
- the amounts of the HMG- CoA reductase inhibitor can be the same or similar to those amounts which are employed for anti-hypercholesterolemic treatment and which are described in the Physicians' Desk Reference (PDR), 52 n d Ed. of the PDR, 1998 (Medical Economics Co), which is incorporated by reference herein in its entirety.
- the doses can be the same or similar to those amounts which are known in the art.
- the HMG-CoA reductase inhibitors and the combination with other active agents can be administered via a wide variety of routes including oral administration, intravenous administration, intranasal administration, injections, ocular administration, and the like.
- a preferred route of delivery is oral administration.
- Oral dosage amounts of the HMG-CoA reductase inhibitor are from about 1 to 200 mg/day, and more preferably from about 5 to 160 mg/day. However, dosage amounts will vary depending on the potency of the specific HMG-CoA reductase inhibitor used as well as other factors as noted above.
- An HMG-CoA reductase inhibitor which has sufficiently greater potency may be given in sub-milligram daily
- the HMG-CoA reductase inhibitor may be administered from 1 to 4 times per day, and preferably once per day.
- the daily dosage amount for simvastatin can be selected from 5 mg, 10 mg, 20 mg, 40 mg, 80 mg and 160 mg; for lovastatin, 10 mg, 20 mg, 40 mg and 80 mg; for fluvastatin sodium, 20 mg, 40 mg and 80 mg; for pravastatin sodium, 10 mg, 20 mg, and 40 mg; and for atorvastatin calcium, 10 mg, 20 mg, and 40 mg.
- Additional Active Agents for Inhibiting Abnormal Bone Resorption Further exemplifying the invention are methods of treatment comprising administering a HMG-CoA reductase inhibitor in combination with one or more active agents for inhibiting bone abnormal resorption selected from the group consisting of organic bisphosphonates, estrogen receptor modulators, and peptide hormones.
- active agents for inhibiting bone resorption can be used in combination with the HMG-CoA reductase inhibitor in a single dosage formulation, or may be administered to the patient in a separate dosage formulation, which allows for concurrent or sequential administration.
- a and X are independently selected from the group consisting of H, OH, halogen, NH2, SH, phenyl, C1-C30 alkyl, C1-C30 substituted alkyl, C1-C10 alkyl or dialkyl substituted NH2, C1-C10 alkoxy,
- the alkyl groups can be straight, branched, or cyclic, provided sufficient atoms are selected for the chemical formula.
- the C1-C30 substituted alkyl can include a wide variety of substituents, nonlimiting examples which include those selected from the group consisting of phenyl, pyridyl, furanyl, pyrrolidinyl, imidazonyl, NH2, Cl-ClO alkyl or dialkyl substituted NH2,
- A can include X and X can include A such that the two moieties can form part of the same cyclic structure.
- the foregoing chemical formula is also intended to encompass complex carbocyclic, aromatic and hetero atom structures for the A and/or X substituents, nonlimiting examples of which include naphthyl, quinolyl, isoquinolyl, adamantyl, and chlorophenylthio.
- Preferred structures are those in which A is selected from the group consisting of H, OH, and halogen, and X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, halogen, and Cl-ClO alkyl or phenyl substituted thio.
- More preferred structures are those in which A is selected from the group consisting of H, OH, and Cl, and X is selected from the group consisting of C1-C30 alkyl, C1-C30 substituted alkyl, Cl, and chlorophenylthio. Most preferred is when A is OH and X is a 3-aminopropyl moiety, so that the resulting compound is a 4-amino-l- hydroxybutylidene-l,l-bisphosphonate, i.e. alendronate.
- salts include those selected from the group consisting of alkali metal, alkaline metal, ammonium, and mono-, di, tri-, or tetra-Cl-C30-alkyl-substituted ammonium.
- Preferred salts are those selected from the group consisting of sodium, potassium, calcium, magnesium, and ammonium salts.
- Nonlimiting examples of derivatives include those selected from the group consisting of esters, hydrates, and amides.
- bisphosphonates as used herein in referring to the therapeutic agents of the present invention are meant to also encompass diphosphonates, biphosphonic acids, and diphosphonic acids, as well as salts and derivatives of these materials.
- the use of a specific nomenclature in referring to the bisphosphonate or bisphosphonates is not meant to limit the scope of the present invention, unless specifically indicated. Because of the mixed nomenclature currently in use by those or ordinary skill in the art, reference to a specific weight or percentage of a bisphosphonate compound in the present invention is on an acid active weight basis, unless indicated otherwise herein.
- the phrase "about 70 mg of a bone resorption inhibiting bisphosphonate selected from the group consisting of alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof, on an alendronic acid active weight basis” means that the amount of the bisphosphonate compound selected is calculated based on 70 mg of alendronic acid.
- Nonlimiting examples of bisphosphonates useful herein include the following :
- Alendronate also known as alendronate sodium or monosodium trihydrate
- alendronate More preferred is alendronate, pharmaceutically acceptable salts thereof, and mixtures thereof.
- Estrogen receptor modulators are known for use in hormone replacement therapy and for their anti-bone resorption benefits.
- Nonlimiting examples of estrogen receptor modulators useful herein include estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.
- Peptide Hormones include estrogen, progestins, estradiol, raloxifene, and tamoxifene, and their pharmaceutically acceptable salts, and mixtures thereof.
- a peptide hormone useful herein is calcitonin, which is approved for use for treating osteoporosis. Both human and salmon calcitonin are useful herein.
- compositions useful in the present invention comprise a therapeutically effective amount of a HMG-CoA reductase inhibitor.
- these compositions also comprise one or more active agents.
- the HMG-CoA reductase inhibitor and any other active agents is typically administered in admixture with suitable pharmaceutical diluents, excipients, or carriers, collectively referred to herein as "carrier materials", selected with respect to the route of administration, i.e. for example oral administration, intravenous administration, intranasal administration, injection, or ocular administration.
- the composition can be administered in the form of tablets, capsules, elixirs, syrups, powders, and the like, and consistent with conventional pharmaceutical practices.
- solid oral forms e.g. tablets, capsules, or powders
- the HMG-CoA reductase inhibitor and any other active agents can be combined with an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like.
- an oral, non-toxic, pharmaceutically acceptable inert carrier such as lactose, starch, sucrose, glucose, methyl cellulose, magnesium stearate, mannitol, sorbitol, croscarmellose sodium and the like.
- liquid oral forms e.g., elixirs and syrups
- the drug component e.g., elixirs and syrups
- Suitable binders can include starch, gelatin, natural sugars such a glucose, anhydrous lactose, free-flow lactose, beta-lactose, and corn sweeteners, natural and synthetic gums, such as acacia, guar, tragacanth or sodium alginate, carboxymethyl cellulose, polyethylene glycol, waxes, and the like.
- Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like.
- the drug or drugs can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and multilamellar vesicles.
- Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.
- the drug or drugs can also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled.
- Active drug or drugs can also be coupled with soluble polymers as targetable carriers.
- Such polymers can include polyvinyl-pyrrolidone, pyran copolymer, polyhydroxy-propyl- methacrylamide-phenol, polyhydroxy-ethyl-aspartamide-phenol, or polyethyleneoxide-polylysine substituted with palmitoyl residues.
- active drug may be coupled to a class of biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
- biodegradable polymers useful in achieving controlled release of a drug, for example, polylactic acid, polyglycolic acid, copolymers of polylactic and polyglycolic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross linked or amphipathic block copolymers of hydrogels.
- the instant invention includes the use of both rapid-release and time-controlled release pharmaceutical formulations.
- the instant invention also encompasses a process for preparing a pharmaceutical composition comprising combining the
- the instant invention also encompasses the use of an HMG-CoA reductase inhibitor and any other active agents for the preparation of a medicament for inhibiting abnormal bone resorption.
- Murine co-cultures of osteoblasts and marrow cells are prepared using the methods of Wesolowski, et al., Exp Cell Res, (1995), 219, pp. 679-686, which is incorporated by reference herein in its entirety.
- Bone marrow cells are harvested from 6-week-old male Balb/C mice by flushing marrow spaces of freshly isolated long bones (tibiae and femora) with ⁇ -MEM (minimal essential media) containing penicillin/streptomycin (100 I.U. ml of each and 20 mM Hepes buffer). The bone marrow cells are suspended in ⁇ -MEM and the cells are filtered through an approximately 70 ⁇ m cell strainer.
- the filtrate is centrifuged at about 300 x g for about 7 minutes.
- the resulting pellet is resuspended in ⁇ -MEM supplemented with fetal calf serum (10 % v/v) and 10 nM 1, 25-(OH) 2 vitamin D 3 .
- fetal calf serum 10 % v/v
- 10 nM 1, 25-(OH) 2 vitamin D 3 10 nM 1, 25-(OH) 2 vitamin D 3 .
- These bone marrow isolates are added to sub-confluent monolayers of osteoblastic MB 1.8 cells in 24 well cell culture plates and cultured for 5 days at 37°C in the presence of 5% C0 2 . Culture media is replenished daily. Fusion of the osteoclast precursor cells from bone marrow (with each other) to form multinucleated osteoclast-like cells typically occurs after about 5 days.
- the compounds to be evaluated are prepared as a solution of the desired concentration in ⁇ -MEM. Examples of compounds
- -21- evaluated include the HMG-CoA reductase inhibitors, lovastatin and simvastatin, as well as compounds that block the effects of these inhibitors, such as D,L-mevalonic acid lactone. Combinations of compounds can also be evaluated.
- the solutions of the compounds to be evaluated are added to the cultures, typically about 0.5 mL/well, on days 5 and 6. No treatment controls (controls not treated with compounds) are prepared by adding equivalent volumes of ⁇ -MEM to the control wells. On day 7, the cultures are evaluated by counting the number of osteoclast-like cells (stained multinucleated cells) or by measuring the tartrate-resistant acid phosphatase (TRAP) activity of the sample via standard fluorescence techniques using a naphthol-based substrate.
- TRIP tartrate-resistant acid phosphatase
- HBS 0.9% NaCl, 10 mM HEPES, pH 7.1,
- Acetate/Tartrate buffer 50 mM sodium acetate, 30 mM sodium tartrate, 0.1% Triton X-100, pH 5.0,
- the cell cultures are fixed for 10 minutes with approximately 0.5 mL of 3.7% formalin at room temperature and then washed once with about 1 mL of the HBS.
- the staining solution (about 0.5 mL) is added to each well and the plates are then incubated for about 10-20 minutes at about 37°C. Following staining, each plate is washed 3
- Multi-nucleated stained cells are counted using an inverted- phase microscope at about 30x magnification.
- the following substrate solution is prepared for measuring TRAP activity via fluorescence:
- Substrate solution A compound having a napthol functional group is dissolved at a concentration of 2.5 mg/ml in HBS buffer.
- the cell cultures are were washed with HBS (about 0.5 ml) and then treated with commercially-available trypsin/EDTA (Gibco BRL, Grand Island, NY, 0.25 ml/well) for 10 minutes at 37°C to selectively release the mononuclear multinuclear cells. Following trypsinization the plates are washed 3 times with Hepes and then blotted on paper towels. Next, about 0.5 mL of the naphthol substrate solution is added to each well and the plates are then incubated at 37°C. Reactions are stopped 1 hour after incubation by addition of 1M NaOH (about 0.05 ml/well).
- the contents of the wells are swirled by placing the plates on an orbital shaker for about 10 minutes to dissolve any precipitates. Fluorescence is determined using a fluorescence plate reader with the excitation wavelength set at 360 nm and the emission wavelength set at 530 nm.
- HMG-CoA reductase inhibitors inhibit osteoclastogenesis.
- All the ingredients except magnesium stearate are blended together in a suitable mixer.
- the powder mixture is then granulated with adequate quantities of granulating solvent(s), e.g. water.
- the wet granulated mass is dried in a suitable dryer.
- the dried granulation is sized through a suitable screen.
- the sized granulation is mixed with magnesium stearate before tableting.
- the tablets may be coated if deemed necessary.
- Additional ingredients that may be added to the above include suitable color and mixtures of colors.
- the composition is useful for inhibiting abnormal bone resorption.
- the simvastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and mevastatin.
- the ingredients are combined and blended together and are compressed using conventional tableting techniques.
- the composition is useful for inhibiting abnormal bone resorption.
- the lovastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and mevastatin.
- the dry ingredients are combined and blended together and encapsulated in a gelatin coating using standard manufacturing techniques.
- the composition is useful for inhibiting abnormal bone resorption.
- the simvastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and mevastatin.
- An oral suspension is prepared by combining the ingredients using standard formulation techniques.
- the composition is useful for inhibiting abnormal bone resorption.
- the lovastatin is replaced by an HMG-CoA reductase inhibitor selected from simvastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and mevastatin.
- the simvastatin is replaced by an HMG-CoA reductase inhibitor selected from lovastatin, pravastatin, fluvastatin, atorvastatin, cerivastsin, and mevastatin.
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99909925A EP1061917A1 (en) | 1998-03-13 | 1999-03-09 | Methods of inhibiting bone resorption |
JP2000535338A JP2002506030A (en) | 1998-03-13 | 1999-03-09 | How to inhibit bone resorption |
CA002323448A CA2323448A1 (en) | 1998-03-13 | 1999-03-09 | Methods of inhibiting bone resorption |
AU29011/99A AU2901199A (en) | 1998-03-13 | 1999-03-09 | Methods of inhibiting bone resorption |
Applications Claiming Priority (12)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7791398P | 1998-03-13 | 1998-03-13 | |
US60/077,913 | 1998-03-13 | ||
US7815798P | 1998-03-16 | 1998-03-16 | |
US60/078,157 | 1998-03-16 | ||
GBGB9809791.8A GB9809791D0 (en) | 1998-05-07 | 1998-05-07 | Methods of inhibiting bone resorption |
GB9809791.8 | 1998-05-07 | ||
GBGB9810885.5A GB9810885D0 (en) | 1998-05-20 | 1998-05-20 | Methods of inhibiting bone resorption |
GB9810885.5 | 1998-05-20 | ||
US9291898P | 1998-07-15 | 1998-07-15 | |
US60/092,918 | 1998-07-15 | ||
GBGB9822699.6A GB9822699D0 (en) | 1998-10-16 | 1998-10-16 | Methods of inhibiting bone resorption |
GB9822699.6 | 1998-10-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1999045923A1 true WO1999045923A1 (en) | 1999-09-16 |
Family
ID=27547312
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1999/005061 WO1999045923A1 (en) | 1998-03-13 | 1999-03-09 | Methods of inhibiting bone resorption |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1061917A1 (en) |
JP (1) | JP2002506030A (en) |
AU (1) | AU2901199A (en) |
CA (1) | CA2323448A1 (en) |
WO (1) | WO1999045923A1 (en) |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001037876A2 (en) * | 1999-11-24 | 2001-05-31 | Bayer Aktiengesellschaft | Methods of ameliorating abnormal bone states |
WO2001052829A2 (en) * | 2000-01-20 | 2001-07-26 | Osteoscreen, Inc. | Statin-type bone growth stimulators |
EP1123717A2 (en) * | 2000-01-26 | 2001-08-16 | Pfizer Products Inc. | Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
EP1127573A1 (en) * | 2000-02-15 | 2001-08-29 | Pfizer Products Inc. | Compostitions and methods for treating osteoporosis |
EP1291017A2 (en) * | 2001-09-10 | 2003-03-12 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
KR20030075715A (en) * | 2002-03-20 | 2003-09-26 | 학교법인 경희대학교 | Lovastatin having growth promotive effects, pharmaceutical composition comprising the same and method for using the same |
EP1351682A1 (en) * | 2001-01-16 | 2003-10-15 | Novogen Research Pty. Ltd. | Regulation of lipids and/or bone density and compositions therefor |
WO2004024165A1 (en) * | 2002-09-09 | 2004-03-25 | Novartis Ag | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
WO2005053681A2 (en) * | 2003-11-28 | 2005-06-16 | Isis Innovation Limited | Novel uses of mevalonate pathway blockers |
WO2005053795A3 (en) * | 2003-11-26 | 2006-04-06 | Depuy Spine Inc | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
WO2014030132A2 (en) | 2012-08-22 | 2014-02-27 | Universidad De Los Andes | Use of statins for periodontal disease and bone regeneration |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
US9683009B2 (en) | 2013-05-02 | 2017-06-20 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
US9717742B2 (en) | 2012-05-07 | 2017-08-01 | The Regents Of The University Of California | Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006503819A (en) * | 2002-08-29 | 2006-02-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Agents and methods for enhancing bone formation |
AU2007217366A1 (en) | 2006-02-27 | 2007-08-30 | The Regents Of The University Of California | Oxysterol compounds and the hedgehog pathway |
-
1999
- 1999-03-09 JP JP2000535338A patent/JP2002506030A/en not_active Withdrawn
- 1999-03-09 EP EP99909925A patent/EP1061917A1/en not_active Withdrawn
- 1999-03-09 WO PCT/US1999/005061 patent/WO1999045923A1/en not_active Application Discontinuation
- 1999-03-09 CA CA002323448A patent/CA2323448A1/en not_active Abandoned
- 1999-03-09 AU AU29011/99A patent/AU2901199A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
TAE WOO J-T, ET AL.: "HMG-COA REDUCTASE INHIBITORS REVERSIBLY INHIBIT FUSION OF MONONUCLEATED PREOSTEOCLASTS AND BONE RESORPTION BY DISRUPTING ACTIN RING FORMATION", BONE, PERGAMON PRESS., OXFORD, GB, vol. 23, no. 05, 1 January 1998 (1998-01-01), GB, pages S549, XP002918923, ISSN: 8756-3282, DOI: 10.1016/S8756-3282(98)00136-7 * |
Cited By (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6376476B1 (en) | 1996-12-13 | 2002-04-23 | Zymogenetics Corporation | Isoprenoid pathway inhibitors for stimulating bone growth |
US7101907B2 (en) | 1996-12-13 | 2006-09-05 | Zymogenetics Corporation | Topical administration of statins for treatment of bone disorders |
WO2001037876A2 (en) * | 1999-11-24 | 2001-05-31 | Bayer Aktiengesellschaft | Methods of ameliorating abnormal bone states |
WO2001037876A3 (en) * | 1999-11-24 | 2002-03-21 | Bayer Ag | Methods of ameliorating abnormal bone states |
WO2001052829A3 (en) * | 2000-01-20 | 2002-05-02 | Osteoscreen Inc | Statin-type bone growth stimulators |
WO2001052829A2 (en) * | 2000-01-20 | 2001-07-26 | Osteoscreen, Inc. | Statin-type bone growth stimulators |
EP1123717A2 (en) * | 2000-01-26 | 2001-08-16 | Pfizer Products Inc. | Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
AU780568B2 (en) * | 2000-01-26 | 2005-04-07 | Pfizer Products Inc. | Compositions and methods for treating osteoporosis and lowering cholesterol |
US6756401B2 (en) | 2000-01-26 | 2004-06-29 | Pfizer Inc. | Compositions and methods for treating osteoporosis and lowering cholesterol |
EP1123717A3 (en) * | 2000-01-26 | 2003-10-15 | Pfizer Products Inc. | Estrogen agonist/antagonist and statin containing compositions for treating osteoporosis and lowering cholesterol |
EP1127573A1 (en) * | 2000-02-15 | 2001-08-29 | Pfizer Products Inc. | Compostitions and methods for treating osteoporosis |
EP1351682A4 (en) * | 2001-01-16 | 2006-01-18 | Novogen Res Pty Ltd | Regulation of lipids and/or bone density and compositions therefor |
EP1351682A1 (en) * | 2001-01-16 | 2003-10-15 | Novogen Research Pty. Ltd. | Regulation of lipids and/or bone density and compositions therefor |
EP1291017A3 (en) * | 2001-09-10 | 2003-07-02 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
EP1291017A2 (en) * | 2001-09-10 | 2003-03-12 | Warner-Lambert Company | Use of statins to inhibit formation of osteoclasts |
KR20030075715A (en) * | 2002-03-20 | 2003-09-26 | 학교법인 경희대학교 | Lovastatin having growth promotive effects, pharmaceutical composition comprising the same and method for using the same |
CN1327844C (en) * | 2002-09-09 | 2007-07-25 | 诺瓦提斯公司 | Combination therapy comprising a bisphosphonate and a HMG-COA reductase inhibitor |
WO2004024165A1 (en) * | 2002-09-09 | 2004-03-25 | Novartis Ag | Combination therapy comprising a bisphosphonate and a hmg-coa reductase inhibitor |
US8273347B2 (en) | 2003-05-13 | 2012-09-25 | Depuy Spine, Inc. | Autologous treatment of degenerated disc with cells |
US8877193B2 (en) | 2003-05-13 | 2014-11-04 | DePuy Synthes Products, LLC. | Transdiscal administration of anti-TNFα antibodies and growth differentiation factors |
US8728523B2 (en) | 2003-05-13 | 2014-05-20 | DePuy Synthes Products, LLC | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7344716B2 (en) | 2003-05-13 | 2008-03-18 | Depuy Spine, Inc. | Transdiscal administration of specific inhibitors of pro-inflammatory cytokines |
US7429378B2 (en) | 2003-05-13 | 2008-09-30 | Depuy Spine, Inc. | Transdiscal administration of high affinity anti-MMP inhibitors |
US8333960B2 (en) | 2003-05-13 | 2012-12-18 | Depuy Spine, Inc. | Treatment of degenerated disc with autologous cells |
US8361467B2 (en) | 2003-07-30 | 2013-01-29 | Depuy Spine, Inc. | Trans-capsular administration of high specificity cytokine inhibitors into orthopedic joints |
US8067397B2 (en) | 2003-08-13 | 2011-11-29 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US7553827B2 (en) | 2003-08-13 | 2009-06-30 | Depuy Spine, Inc. | Transdiscal administration of cycline compounds |
US9532994B2 (en) | 2003-08-29 | 2017-01-03 | The Regents Of The University Of California | Agents and methods for enhancing bone formation by oxysterols in combination with bone morphogenic proteins |
USRE49219E1 (en) | 2003-11-26 | 2022-09-27 | DePuy Synthes Products, Inc. | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005053795A3 (en) * | 2003-11-26 | 2006-04-06 | Depuy Spine Inc | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
US8895540B2 (en) | 2003-11-26 | 2014-11-25 | DePuy Synthes Products, LLC | Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
WO2005053681A3 (en) * | 2003-11-28 | 2005-10-13 | Isis Innovation | Novel uses of mevalonate pathway blockers |
WO2005053681A2 (en) * | 2003-11-28 | 2005-06-16 | Isis Innovation Limited | Novel uses of mevalonate pathway blockers |
US9526737B2 (en) | 2007-12-03 | 2016-12-27 | The Regents Of The University Of California | Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and Wnt signaling |
US8986696B2 (en) | 2007-12-21 | 2015-03-24 | Depuy Mitek, Inc. | Trans-capsular administration of p38 map kinase inhibitors into orthopedic joints |
US9717742B2 (en) | 2012-05-07 | 2017-08-01 | The Regents Of The University Of California | Oxysterol analogue OXY133 induces osteogenesis and hedgehog signaling and inhibits adipogenesis |
EP2887932A4 (en) * | 2012-08-22 | 2015-12-30 | Univ Los Andes | Use of statins for periodontal disease and bone regeneration |
US10918620B2 (en) | 2012-08-22 | 2021-02-16 | David Rafael ROSENBERG MESSINA | Use of statins for periodontal disease and bone regeneration |
WO2014030132A2 (en) | 2012-08-22 | 2014-02-27 | Universidad De Los Andes | Use of statins for periodontal disease and bone regeneration |
US9683009B2 (en) | 2013-05-02 | 2017-06-20 | The Regents Of The University Of California | Bone-selective osteogenic oxysterol-bone targeting agents |
Also Published As
Publication number | Publication date |
---|---|
EP1061917A1 (en) | 2000-12-27 |
JP2002506030A (en) | 2002-02-26 |
AU2901199A (en) | 1999-09-27 |
CA2323448A1 (en) | 1999-09-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1061917A1 (en) | Methods of inhibiting bone resorption | |
US5994329A (en) | Method for inhibiting bone resorption | |
AU757104B2 (en) | Compositions and methods for inhibiting bone resorption | |
US6432932B1 (en) | Method for inhibiting bone resorption | |
JP2001253827A (en) | Composition and method for treating osteoporosis | |
CA2294595C (en) | Inhibiting bone resorption | |
US20010025028A1 (en) | Methods of inhibiting bone resorption | |
CA2403735A1 (en) | Methods for identifying compounds useful for inhibiting geranylgeranyl diphosphate synthase | |
US20040180862A1 (en) | Compositions and methods for inhibiting bone resorption | |
AU741818B2 (en) | Method for inhibiting bone resorption | |
US20070004681A1 (en) | Methods for treating arthritic conditions | |
AU2002303925A1 (en) | Compositions and methods for inhibiting bone resorption | |
CA2349733A1 (en) | Inhibition bone resorption | |
AU2005227418A1 (en) | Method for inhibiting bone resorption |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AU AZ BA BB BG BR BY CA CN CU CZ EE GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK SL TJ TM TR TT UA US UZ VN YU |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1999909925 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 535338 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 29011/99 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2323448 Country of ref document: CA Ref country code: CA Ref document number: 2323448 Kind code of ref document: A Format of ref document f/p: F |
|
NENP | Non-entry into the national phase |
Ref country code: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 1999909925 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999909925 Country of ref document: EP |